title: Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
authors.affiliation: Department of Pediatric Immunology & Rheumatology, Wilhelmina Children's Hospital University Medical Center, Utrecht, The Netherlands.
authors.forename: Annet
authors.initials: A
authors.lastname: van Royen-Kerkhof
authors.forename: Bas Sj
authors.initials: BS
authors.lastname: Vastert
authors.forename: Joost F
authors.initials: JF
authors.lastname: Swart
authors.forename: Nico M
authors.initials: NM
authors.lastname: Wulffraat
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001691:Biological Therapy / Q000379:methods* / Q000639:trends; D002648:Child; D003362:Cost-Benefit Analysis; D000068800:Etanercept; D005060:Europe; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000191:economics / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000191:economics / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; C541220:canakinumab; D000068800:Etanercept